Sartorius (SARTF) Stock Rating Lowered by Zacks Investment Research

Sartorius (OTCMKTS:SARTF) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a report issued on Friday, reports.

According to Zacks, “Sartorius AG is a pharmaceutical and laboratory equipment supplier. The company manufactures equipment for biomolecular and microbial separations, cell culture, concentration, fermentation and purification. Sartorius AG is headquartered in Goettingen, Germany. “

Several other equities research analysts have also commented on the stock. ValuEngine raised shares of Sartorius from a “hold” rating to a “buy” rating in a research report on Friday, March 15th. DZ Bank reaffirmed a “sell” rating on shares of Sartorius in a research report on Tuesday, April 2nd.

SARTF opened at $159.56 on Friday. The company has a current ratio of 1.57, a quick ratio of 0.90 and a debt-to-equity ratio of 0.92. The stock has a market cap of $5.46 billion, a price-to-earnings ratio of 52.83 and a beta of 0.07. Sartorius has a 52-week low of $109.50 and a 52-week high of $159.56.

Sartorius (OTCMKTS:SARTF) last posted its earnings results on Tuesday, February 19th. The company reported $0.82 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.84 by ($0.02). The company had revenue of $470.78 million for the quarter, compared to the consensus estimate of $478.80 million. Sartorius had a net margin of 9.36% and a return on equity of 18.37%. As a group, analysts expect that Sartorius will post 3.31 EPS for the current year.

About Sartorius

There is no company description available for Sartorius AG.

Featured Article: What is the return on assets formula?

Get a free copy of the Zacks research report on Sartorius (SARTF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit